Literature DB >> 28928007

Removal of uremic retention products by hemodialysis is coupled with indiscriminate loss of vital metabolites.

Zhi-Hao Zhang1, Jia-Rong Mao2, Hua Chen3, Wei Su4, Yuan Zhang5, Li Zhang5, Dan-Qian Chen3, Ying-Yong Zhao6, Nosratola D Vaziri7.   

Abstract

BACKGROUND: Although dialysis ameliorates uremia and fluid and electrolytes disorders, annual mortality rate remains high in dialysis population reflecting its shortcoming in replacing renal function. Unlike the normal kidney, dialysis causes dramatic shifts in volume and composition of body fluids and indiscriminate removal of vital solutes. Present study was undertaken to determine the impact of hemodialysis on plasma metabolites in end-stage renal disease (ESRD) patients.
METHODS: 80 hemodialysis patients and 80 age/gender-matched healthy controls were enrolled in the study. Using ultra performance liquid chromatography-high-definition mass spectrometry, we measured plasma metabolites before, during, and after hemodialysis procedure and in blood entering and leaving the dialysis filter.
RESULTS: Principal component analysis revealed significant difference in concentration of 214 metabolites between healthy control and ESRD patients' pre-dialysis plasma (126 increased and 88 reduced in ESRD group). Comparison of post-dialysis with pre-dialysis data revealed significant changes in the 362 metabolites. Among ESI+ metabolites 195 decreased and 55 increased and among ESI- metabolites 82 decreased and 30 increased following hemodialysis. Single blood passage through the dialyzer caused significant changes in 323 metabolites. Comparison of ESRD patients' post-hemodialysis with healthy subjects' data revealed marked differences in metabolic profiles. We identified 55 of the 362 differential metabolites including well known uremic toxins, waste products and vital biological compounds.
CONCLUSION: In addition to uremic toxins and waste products hemodialysis removes large number of identified and as-yet un-identified metabolites. Depletion of vital biological compounds by dialysis may contribute to the high morbidity and annual mortality rate in this population.
Copyright © 2017 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chronic kidney disease; Dialysis; End-stage renal disease; Metabolomics; Ultra performance liquid chromatography

Mesh:

Year:  2017        PMID: 28928007     DOI: 10.1016/j.clinbiochem.2017.09.012

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  13 in total

1.  Amelioration of diabetic nephropathy in db/db mice treated with tibetan medicine formula Siwei Jianghuang Decoction Powder extract.

Authors:  Xianrong Lai; Dong Tong; Xiaopeng Ai; Jiasi Wu; Yu Luo; Fang Zuo; Zhicheng Wei; Yanqiao Li; Wanyi Huang; Wenqian Wang; Qing Jiang; Xianli Meng; Yong Zeng; Ping Wang
Journal:  Sci Rep       Date:  2018-11-12       Impact factor: 4.379

2.  Unilateral ureteral obstruction causes gut microbial dysbiosis and metabolome disorders contributing to tubulointerstitial fibrosis.

Authors:  Lin Chen; Dan-Qian Chen; Jing-Ru Liu; Jun Zhang; Nosratola D Vaziri; Shougang Zhuang; Hua Chen; Ya-Long Feng; Yan Guo; Ying-Yong Zhao
Journal:  Exp Mol Med       Date:  2019-03-27       Impact factor: 8.718

Review 3.  Aryl hydrocarbon receptor activation mediates kidney disease and renal cell carcinoma.

Authors:  Hui Zhao; Lin Chen; Tian Yang; Ya-Long Feng; Nosratola D Vaziri; Bao-Li Liu; Qing-Quan Liu; Yan Guo; Ying-Yong Zhao
Journal:  J Transl Med       Date:  2019-09-05       Impact factor: 5.531

4.  Exploring blood alterations in chronic kidney disease and haemodialysis using metabolomics.

Authors:  Yoric Gagnebin; David A Jaques; Serge Rudaz; Sophie de Seigneux; Julien Boccard; Belén Ponte
Journal:  Sci Rep       Date:  2020-11-11       Impact factor: 4.379

5.  An Integrated Lipidomics and Phenotype Study Reveals Protective Effect and Biochemical Mechanism of Traditionally Used Alisma orientale Juzepzuk in Chronic Kidney Disease.

Authors:  Fang Dou; Hua Miao; Jing-Wen Wang; Lin Chen; Ming Wang; Hua Chen; Ai-Dong Wen; Ying-Yong Zhao
Journal:  Front Pharmacol       Date:  2018-02-08       Impact factor: 5.810

6.  Astragaloside IV ameliorates early diabetic nephropathy by inhibition of MEK1/2-ERK1/2-RSK2 signaling in streptozotocin-induced diabetic mice.

Authors:  Gaofeng Song; Pengxun Han; Huili Sun; Mumin Shao; Xuewen Yu; Wenjing Wang; Dongtao Wang; Wuyong Yi; Na Ge; Shunmin Li; Tiegang Yi
Journal:  J Int Med Res       Date:  2018-06-13       Impact factor: 1.671

7.  The metabolomic quest for a biomarker in chronic kidney disease.

Authors:  Robert Davies
Journal:  Clin Kidney J       Date:  2018-06-02

8.  Renoprotective effect of Zhenwu decoction against renal fibrosis by regulation of oxidative damage and energy metabolism disorder.

Authors:  Shasha Li; Xue Xiao; Ling Han; Yiming Wang; Guoan Luo
Journal:  Sci Rep       Date:  2018-10-02       Impact factor: 4.379

9.  Prescribing Hemodialysis or Hemodiafiltration: When One Size Does Not Fit All the Proposal of a Personalized Approach Based on Comorbidity and Nutritional Status.

Authors:  Giorgina Barbara Piccoli; Louise Nielsen; Lurilyn Gendrot; Antioco Fois; Emanuela Cataldo; Gianfranca Cabiddu
Journal:  J Clin Med       Date:  2018-10-08       Impact factor: 4.241

Review 10.  Microbiome-metabolome reveals the contribution of gut-kidney axis on kidney disease.

Authors:  Yuan-Yuan Chen; Dan-Qian Chen; Lin Chen; Jing-Ru Liu; Nosratola D Vaziri; Yan Guo; Ying-Yong Zhao
Journal:  J Transl Med       Date:  2019-01-03       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.